Our results driven ethic and approach is what separates KCSA from other communications firms.
Cellectis (NASDAQ: CLLS) is a biopharmaceutical company that develops immunotherapies based on gene edited CAR T-cells (UCART). The Company hired KCSA to create a highly targeted media relations campaign to establish Cellectis as a major biotech player in the U.S. – one that’s on the cusp of spearheading a fundamental change in how diseases (i.e. cancers) are treated – to drive institutional investment.
As part of the program, Cellectis wanted to draw significant media attention to the results of two successful compassionate care cases where gene editing technology that Cellectis developed, UCART19, cured infants with Leukemia in the U.K.
KCSA’s approach to securing media coverage for Cellectis is multi-tiered. Prior to the Company’s announcement of its first successful compassionate care case, KCSA arranged for multiple introductory “background” interviews for Cellectis’ CEO to walk reporters through the Company’s work to-date and make sure that they had Cellectis on their radar in the weeks / months to come.
During the actual announcements of the compassionate care cases, KCSA worked closely to share the news under embargo with select top-tier business / financial reporters (i.e. The New York Times, Wall Street Journal, Financial Times, Reuters, CNBC, etc.) so that Cellectis had a steady stream of impressive coverage run on the days subsequent to the announcements.
KCSA also secured a speaking slot for the CEO at the 2017 Milken Institute Global Conference and continues to support Cellectis at all major biotech events. Additionally, KCSA regularly secures bylined article opportunities (i.e. TechCrunch), submits the CEO as a speaker for TED talks, etc.
As a result of KCSA pitching the Cellectis story over the course of our engagement, the Company has been prominently featured in nearly every major international news outlet. Top-tier placements include The New York Times, Wall Street Journal, CNBC, National Geographic, Al Jazeera, Fox News, Bloomberg, Financial Times, Reuters, Newsweek and Washington Post.
From KCSA’s efforts, we’ve solidified long-term relationships with reporters in both the top-tier business / financial press, as well as in the key trade / vertical industry outlets, to make sure that Cellectis’ corporate and scientific work remains top-of-mind in the media. As a result, KCSA has effectively positioned Cellectis’ CEO and scientific team as pioneers in the gene editing space, generating millions of impressions for Cellectis to date.